{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:52:22Z","timestamp":1790009542666,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-12831-4","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T04:02:18Z","timestamp":1725249738000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Irinotecan plus raltitrexed as second-line treatment in locally advanced or metastatic colorectal cancer patients: a prospective open-label, single-arm, multi-center, phase II study"],"prefix":"10.1186","volume":"24","author":[{"given":"Yu","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zan","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuee","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingdong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglei","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"12831_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"12831_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14:29\u201337.","journal-title":"Lancet Oncol"},{"key":"12831_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303\u201312.","journal-title":"Lancet"},{"key":"12831_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229\u201337.","journal-title":"J Clin Oncol"},{"key":"12831_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andr\u00e9 T, Achille E. FOLFIRI followed by FOLFOX6 or the reverse sequence in Advanced Colorectal Cancer: a Randomized GERCOR Study. J Clin Oncol. 2004;22:229\u201337.","journal-title":"J Clin Oncol"},{"key":"12831_CR6","unstructured":"Baba H et al. 2014 ASCO GI Abstract 463."},{"key":"12831_CR7","doi-asserted-by":"crossref","unstructured":"Zhang X, Duan R. Yusheng Wang. FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial. Ther Adv Med Oncol. 2022;14:1\u201312.","DOI":"10.1177\/17588359211068737"},{"key":"12831_CR8","doi-asserted-by":"crossref","unstructured":"Huang M, Yang Y, Zhu X. A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer. Asia-Pac J Clin Oncol. 2021;1\u20139.","DOI":"10.1111\/ajco.13511"},{"key":"12831_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/bjc.1998.421","volume":"77","author":"D Cunningham","year":"1998","unstructured":"Cunningham D. Mature results from three large controlled studies with raltitrexed (\u2018Tomudex\u2019). Br Joumal Cancer. 1998;77:15\u201321.","journal-title":"Br Joumal Cancer"},{"key":"12831_CR10","first-page":"18","volume":"6","author":"JW Yu","year":"2012","unstructured":"Yu JW. The observation of raltitrexed as second-line chemotherapy for advanced colorectal cancer. Chin J Mod Drug Appl. 2012;6:18\u20139.","journal-title":"Chin J Mod Drug Appl"},{"issue":"7","key":"12831_CR11","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/annonc\/mdf183","volume":"13","author":"J-F Seitz","year":"2002","unstructured":"Seitz J-F, Bennouna J. Multicenter non-randomized phaseIIstudy of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. Ann Oncol. 2002;13(7):1072\u20139.","journal-title":"Ann Oncol"},{"key":"12831_CR12","doi-asserted-by":"crossref","unstructured":"Cascinu1 S, Graziano2 F, Ferra\u00f9 F. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Ann Oncol. 2002;13(5):716\u201320.","DOI":"10.1093\/annonc\/mdf091"},{"key":"12831_CR13","doi-asserted-by":"crossref","unstructured":"Neri B 1, Doni L, Fulignati C. Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial. Anticancer Drugs. 2002;13(7):719\u201324.","DOI":"10.1097\/00001813-200208000-00006"},{"issue":"1","key":"12831_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1385\/MO:21:1:59","volume":"21","author":"C Massacesi","year":"2004","unstructured":"Daniele Santini 1, Massacesi C. Rolando Maria D\u2019Angelillo. Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study. Med Oncol. 2004;21(1):59\u201366.","journal-title":"Med Oncol"},{"issue":"9","key":"12831_CR15","first-page":"1424","volume":"13","author":"L C.Carnaghi","year":"2002","unstructured":"C.Carnaghi L, Rimassa I, Garassino. P.Irinotecan and raltitrexed: an active combination in advanced colorectal cancerAnn. Oncol. 2002;13(9):1424\u20139.","journal-title":"Oncol"},{"issue":"8","key":"12831_CR16","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/sj.bjc.6601713","volume":"90","author":"J Feliu","year":"2004","unstructured":"Feliu J, Salud A, Escudero P. Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study. Br J Cancer. 2004;90(8):1502\u20137.","journal-title":"Br J Cancer"},{"key":"12831_CR17","unstructured":"Silvana Chiara MT, Nobile L, Tomasello. Phase II trial of Irinotecan and Raltitrexed in Chemotherapy-naive Advanced Colorectal Cancer Anticancer Res. 2005;25(2B):1391\u20136."},{"key":"12831_CR18","first-page":"6","volume":"17","author":"JL Wang","year":"2012","unstructured":"Wang JL, Li J, Qin SK, et al. Randomized multicenter phase III trial of oxaliplatin plus raltitrexed verus oxaliplatin plus fluorouracil and leucovorin for advanced colorectal cancer. Chin Clin Oncol. 2012;17:6\u201311.","journal-title":"Chin Clin Oncol"},{"key":"12831_CR19","doi-asserted-by":"crossref","unstructured":"Aparicio1 J, Vicent JM, Maestu I. Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. Ann Oncol. 2003;14(7):1121\u20135.","DOI":"10.1093\/annonc\/mdg285"},{"key":"12831_CR20","doi-asserted-by":"crossref","unstructured":"Xie S, Han G, Fan Z, He L, Xu W, Qin Z. Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer. Med Oncol. 2014;31:35. 21. Yuguo Liu Lijuan Luan Xingli Wang. A randomized Phase II clinical study of combining panitumumab and bevacizumab, plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for patients with metastatic colorectal cancer and KRAS mutation. OncoTargets and Therapy 2015; 8:1061\u20131068.","DOI":"10.2147\/OTT.S81442"},{"key":"12831_CR21","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1470-2045(10)70181-9","volume":"11","author":"K Muro","year":"2010","unstructured":"Muro K, Boku N, Shimada Y, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2\/3 non-inferiority study (FIRIS study). Lancet Oncol. 2010;11:853\u201360.","journal-title":"Lancet Oncol"},{"key":"12831_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1172\/JCI113308","volume":"81","author":"RB Diasio","year":"1988","unstructured":"Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest. 1988;81:47\u201351.","journal-title":"J Clin Invest"},{"key":"12831_CR23","first-page":"4363","volume":"9","author":"ABP van Kuilenburg","year":"2003","unstructured":"van Kuilenburg ABP, Meinsma R, Zonnenberg BA, et al. Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res. 2003;9:4363\u20137.","journal-title":"Clin Cancer Res"},{"key":"12831_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3816\/CCC.2004.n.018","volume":"4","author":"H Ezzeldin","year":"2004","unstructured":"Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer. 2004;4:181\u20139.","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"12831_CR25","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/annonc\/mdt479","volume":"25","author":"D Ransom","year":"2014","unstructured":"Ransom D, Wilson K, Fournier M, Simes RJ. Final results of Australasian gastrointestinal trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Ann Oncol. 2014;25(1):117\u201321.","journal-title":"Ann Oncol"},{"key":"12831_CR26","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1093\/annonc\/mds236","volume":"23","author":"HJ Schmoll","year":"2012","unstructured":"Schmoll HJ, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23:2479\u2013516.","journal-title":"Ann Oncol"},{"issue":"5","key":"12831_CR27","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/S1470-2045(18)30140-2","volume":"19","author":"R-H Xu","year":"2018","unstructured":"Xu R-H, Muro K, Morita S. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2018;19(5):660\u201371.","journal-title":"Lancet Oncol"},{"issue":"5","key":"12831_CR28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1023\/A:1011194712661","volume":"12","author":"W Scheithauer","year":"2001","unstructured":"Scheithauer W, Kornek GV, Schuell B, et al. Second-line treatment with oxaliplatin\u2009+\u2009raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine\/leucovorinbased chemotherapy. Ann Oncol. 2001;12(5):709\u201314.","journal-title":"Ann Oncol"},{"issue":"2c","key":"12831_CR29","first-page":"1139","volume":"24","author":"A Laudani","year":"2004","unstructured":"Laudani A, Gebbia V, Leonardi V, et al. Activity and toxicity of oxaliplatin plus raltitrexed in 5-fluorouracil refractory metastatic colorectal adeno-carcinoma. Anticancer Res. 2004;24(2c):1139\u201342.","journal-title":"Anticancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12831-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12831-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12831-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T04:08:26Z","timestamp":1725250106000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12831-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12831"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12831-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3886684\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"22 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This clinical study was approved by Committee of Clinical Trials of The First Hospital of China Medical University. Informed consent was obtained from all subjects and\/or their legal guardian(s). The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1082"}}